CGEN

Compugen Ltd. [CGEN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CGEN Stock Summary

Earnings have grown 346.12% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Became profitable this year

Earnings are expected to fall -100% next year

Profit margins (-4.21%) are lower than the previous year (-0.56%)

CGEN has less than 1 year of cash runway

Top 10 Correlated ETFs

CGEN

Top 10 Correlated Stocks

CGEN

In the News

CGEN Financial details

Company Rating

Buy

Market Cap

190.7M

Income

-18.75M

Revenue

33.46M

Book val./share

0.74

Cash/share

0.58

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

13 May 2024

P/E

-5.06

Forward P/E

PEG

1.16

P/S

21.32

P/B

P/C

3.3

P/FCF

-6.84

Quick Ratio

5.81

Current Ratio

5.81

Debt / Equity

0.02

LT Debt / Equity

0.01

EPS (TTM)

-0.22

EPS next Y

EPS next Q

EPS this Y

-46.15%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-200%

SMA20

-33.33%

SMA50

SMA100

100%

Inst Own

10.68%

Inst Trans

0.81%

ROA

-47%

ROE

-48%

ROC

-0.6%

Gross Margin

87%

Oper. Margin

-460%

Profit Margin

-421%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.53-3.03

52W High

52W Low

RSI

Rel Volume

0.53

Avg Volume

626.13K

Volume

329.51K

Perf Week

-18.86%

Perf Month

-25.2%

Perf Quarter

162.69%

Perf Half Y

135.26%

Beta

2.679

Volatility

0.13%, 0.27%

Prev Close

-5.67%

Price

1.915

Change

-2.3%

CGEN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0.03	0.07	0.09	0.38
Net income per share	-0.43	-0.34	-0.39	-0.39	-0.21
Operating cash flow per share	-0.44	-0.36	-0.27	-0.4	-0.41
Free cash flow per share	-0.44	-0.36	-0.27	-0.4	-0.41
Cash per share	1.22	1.56	1.39	0.96	0.58
Book value per share	0.6	1.5	1.27	0.9	0.75
Tangible book value per share	0.6	1.5	1.27	0.9	0.75
Share holders equity per share	0.6	1.5	1.27	0.9	0.75
Interest debt per share	0.06	0.04	0.03	0.02	0.02
Market cap	379.27M	963.85M	362.08M	61.95M	175.27M
Enterprise value	338.97M	959.87M	357.03M	52.81M	162.36M
P/E ratio	-13.87	-35.36	-11.01	-1.84	-9.35
Price to sales ratio	0	481.92	60.35	8.26	5.24
POCF ratio	-13.6	-34.03	-15.92	-1.8	-4.87
PFCF ratio	-13.52	-33.84	-15.71	-1.77	-4.85
P/B Ratio	9.9	8.05	3.39	0.8	2.67
PTB ratio	9.9	8.05	3.39	0.8	2.67
EV to sales	0	479.94	59.5	7.04	4.85
Enterprise value over EBITDA	-11.74	-30.48	-10.18	-1.49	-12.97
EV to operating cash flow	-12.15	-33.89	-15.69	-1.53	-4.51
EV to free cash flow	-12.09	-33.7	-15.49	-1.51	-4.49
Earnings yield	-0.07	-0.03	-0.09	-0.54	-0.11
Free cash flow yield	-0.07	-0.03	-0.06	-0.56	-0.21
Debt to equity	0.09	0.03	0.03	0.02	0.02
Debt to assets	0.07	0.02	0.02	0.02	0.01
Net debt to EBITDA	1.4	0.13	0.14	0.26	1.03
Current ratio	6.6	12.27	7.21	7.23	4.36
Interest coverage	-902.47	-749.9	-1.4K	-1.31K	-419.1
Income quality	1.02	0.95	0.67	1.02	1.92
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	4.9	1.81	1.38	0.29
Research and developement to revenue	0	11.38	4.78	4.09	1.03
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.01	0.01	0.01	0
Capex to revenue	0	-0.08	-0.05	-0.06	-0.01
Capex to depreciation	-0.16	-0.23	-0.63	-1.01	-0.36
Stock based compensation to revenue	0	1.39	0.71	0.58	0.11
Graham number	2.41	3.41	3.34	2.8	1.9
ROIC	-0.62	-0.23	-0.3	-0.43	-0.37
Return on tangible assets	-0.51	-0.2	-0.25	-0.36	-0.15
Graham Net	0.99	0.62	0.48	0.37	0.47
Working capital	38.18M	118.57M	106.13M	74.21M	88.31M
Tangible asset value	38.32M	119.78M	106.69M	77.68M	65.56M
Net current asset value	29.56M	110.56M	97.75M	69.63M	58.8M
Invested capital	0.09	0.03	0.03	0.02	0.02
Average receivables	1.01M	2.89M	5.06M	3.94M	31.87M
Average payables	2.02M	1.25M	3.02M	3.2M	2.64M
Average inventory	-1.06M	-60.03M	-114.63M	-91.31M	-36.32M
Days sales outstanding	0	850.09	332.15	117.63	668.91
Days payables outstanding	401.54	8.6K	2.48K	663.74	515.42
Days of inventory on hand	-287.87	-725.67K	-59.02K	-27.2K	0
Receivables turnover	0	0.43	1.1	3.1	0.55
Payables turnover	0.91	0.04	0.15	0.55	0.71
Inventory turnover	-1.27	0	-0.01	-0.01	0
ROE	-0.71	-0.23	-0.31	-0.43	-0.29
Capex per share	0	0	0	-0.01	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.09	0	0	0	0.38
Net income per share	-0.04	-0.11	-0.11	-0.11	0.11
Operating cash flow per share	-0.27	0	0	0	0
Free cash flow per share	-0.27	0	0	0	0
Cash per share	0.96	0.86	0.76	0.65	0.58
Book value per share	0.9	0.8	0.71	0.6	0.74
Tangible book value per share	0.9	0.8	0.71	0.6	0.74
Share holders equity per share	0.9	0.8	0.71	0.6	0.74
Interest debt per share	0.03	0.01	0.02	0.02	0.02
Market cap	62M	60.81M	99.39M	82.13M	176.83M
Enterprise value	52.86M	64.39M	39.01M	35.76M	163.93M
P/E ratio	-5.01	-1.63	-2.68	-2.08	4.55
Price to sales ratio	8.27	0	0	0	5.28
POCF ratio	-2.69	0	0	0	0
PFCF ratio	-2.65	0	0	0	0
P/B Ratio	0.8	0.88	1.6	1.54	2.7
PTB ratio	0.8	0.88	1.6	1.54	2.7
EV to sales	7.05	0	0	0	4.9
Enterprise value over EBITDA	-14.98	-6.35	-3.82	-3.36	9.12
EV to operating cash flow	-2.3	0	0	0	0
EV to free cash flow	-2.26	0	0	0	0
Earnings yield	-0.05	-0.15	-0.09	-0.12	0.05
Free cash flow yield	-0.38	0	0	0	0
Debt to equity	0.02	0.03	0.03	0.03	0.02
Debt to assets	0.02	0.02	0.02	0.02	0.01
Net debt to EBITDA	2.59	-0.35	5.91	4.36	-0.72
Current ratio	7.23	7.13	6.43	5.81	4.36
Interest coverage	-7.13	12.54	0	0	0
Income quality	7.45	0	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.34	0	0	0	0.07
Research and developement to revenue	0.98	0	0	0	0.33
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.02	0	0	0	0
Capex to revenue	-0.05	0	0	0	0
Capex to depreciation	-6.5	0	0	0	0
Stock based compensation to revenue	0.58	0	0	0	0
Graham number	0.85	1.39	1.3	1.23	1.35
ROIC	-0.04	-0.14	-0.16	-0.19	0.14
Return on tangible assets	-0.03	-0.11	-0.12	-0.15	0.08
Graham Net	0.37	0.69	0.6	0.5	0.47
Working capital	74.21M	65.72M	58.6M	49.89M	88.31M
Tangible asset value	77.68M	69.21M	62M	53.23M	65.56M
Net current asset value	69.63M	61.34M	54.35M	45.89M	58.8M
Invested capital	0.02	0.03	0.03	0.03	0.02
Average receivables	2.62M	2.27M	2.49M	2.81M	32.04M
Average payables	7.15M	5.94M	5.89M	5.73M	6.64M
Average inventory	-37.74M	-37.39M	-2.49M	-2.81M	-1.38M
Days sales outstanding	29	0	0	0	164.94
Days payables outstanding	163.66	0	0	0	157.28
Days of inventory on hand	-6.71K	0	0	0	0
Receivables turnover	3.1	0	0	0	0.55
Payables turnover	0.55	0	0	0	0.57
Inventory turnover	-0.01	0	0	0	0
ROE	-0.04	-0.13	-0.15	-0.19	0.15
Capex per share	0	0	0	0	0

CGEN Frequently Asked Questions

What is Compugen Ltd. stock symbol ?

Compugen Ltd. is a IL stock and trading under the symbol CGEN

What is Compugen Ltd. stock quote today ?

Compugen Ltd. stock price is $1.915 today.

Is Compugen Ltd. stock public?

Yes, Compugen Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 626.13K
Market Capitalization 190.7M
Employee 68
CEO Dr. Anat Cohen-Dayag Ph.D.
Headquarters Holon,IL
IPO Date 2000-08-11
Website https://cgen.com

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.